JASN:透析患者的心脏骤停风险可能归因于遗传

2015-11-23 MedSci译 MedSci原创

与普通人群相比,透析患者的心脏骤停率是普通人群的20倍。研究人员考虑到透析患者发生心脏骤停是否与遗传因素有关。研究人员收集了647457例慢性透析的样本,并从中确定了5117对来自同一个家庭的患者。这些患者每一个都有来自相同人群的匹配对照参与者。McNemar测试被用来比较的家族相关和不相关的匹配者对之间心脏骤停的危险。与表型匹配的无关对照相比,没有共同居住过的的基因相关的家庭成员心脏骤停比值比为

与普通人群相比,透析患者的心脏骤停率是普通人群的20倍。研究人员考虑到透析患者发生心脏骤停是否与遗传因素有关。

研究人员收集了647457例慢性透析的样本,并从中确定了5117对来自同一个家庭的患者。这些患者每一个都有来自相同人群的匹配对照参与者。McNemar测试被用来比较的家族相关和不相关的匹配者对之间心脏骤停的危险。

与表型匹配的无关对照相比,没有共同居住过的的基因相关的家庭成员心脏骤停比值比为1.88(95%置信区间[95%Cl],1.25〜2.84)。有血亲关系的家庭成员并且居住在同一个环境中比值比为1.66(95%Cl,1.20至2.28)。遗传无关的配偶,但共同生活在同一环境中,心脏骤停的比值比为0.95(95%Cl,0.60至1.59)。

透析患者的心脏骤停风险可能是由于遗传因素。还需要更多的研究来确定终末期肾病心血管疾病的危险的候选基因。

原始出处:

Kevin E. Chan,Christopher Newton-Cheh,James F. Gusella,et al.Heritability of Risk for Sudden Cardiac Arrest in ESRD,JASN,2015.11.23

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941269, encodeId=6f101941269d1, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 17 00:47:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44387, encodeId=63784438e45, content=请问怎么获得原文呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aabe1667714, createdName=尼土土, createdTime=Wed Dec 02 11:26:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570586, encodeId=447215e058696, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Wed Nov 25 09:47:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43606, encodeId=422c436064c, content=同问呀……, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3601615208, createdName=dearluodi, createdTime=Tue Nov 24 00:59:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43602, encodeId=bbe943602e4, content=电解质等没有影响?, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Nov 23 22:45:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2016-01-17 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941269, encodeId=6f101941269d1, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 17 00:47:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44387, encodeId=63784438e45, content=请问怎么获得原文呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aabe1667714, createdName=尼土土, createdTime=Wed Dec 02 11:26:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570586, encodeId=447215e058696, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Wed Nov 25 09:47:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43606, encodeId=422c436064c, content=同问呀……, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3601615208, createdName=dearluodi, createdTime=Tue Nov 24 00:59:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43602, encodeId=bbe943602e4, content=电解质等没有影响?, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Nov 23 22:45:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2015-12-02 尼土土

    请问怎么获得原文呢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1941269, encodeId=6f101941269d1, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 17 00:47:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44387, encodeId=63784438e45, content=请问怎么获得原文呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aabe1667714, createdName=尼土土, createdTime=Wed Dec 02 11:26:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570586, encodeId=447215e058696, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Wed Nov 25 09:47:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43606, encodeId=422c436064c, content=同问呀……, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3601615208, createdName=dearluodi, createdTime=Tue Nov 24 00:59:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43602, encodeId=bbe943602e4, content=电解质等没有影响?, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Nov 23 22:45:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941269, encodeId=6f101941269d1, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 17 00:47:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44387, encodeId=63784438e45, content=请问怎么获得原文呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aabe1667714, createdName=尼土土, createdTime=Wed Dec 02 11:26:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570586, encodeId=447215e058696, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Wed Nov 25 09:47:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43606, encodeId=422c436064c, content=同问呀……, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3601615208, createdName=dearluodi, createdTime=Tue Nov 24 00:59:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43602, encodeId=bbe943602e4, content=电解质等没有影响?, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Nov 23 22:45:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2015-11-24 dearluodi

    同问呀……

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1941269, encodeId=6f101941269d1, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sun Jan 17 00:47:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44387, encodeId=63784438e45, content=请问怎么获得原文呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aabe1667714, createdName=尼土土, createdTime=Wed Dec 02 11:26:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570586, encodeId=447215e058696, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Wed Nov 25 09:47:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43606, encodeId=422c436064c, content=同问呀……, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3601615208, createdName=dearluodi, createdTime=Tue Nov 24 00:59:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43602, encodeId=bbe943602e4, content=电解质等没有影响?, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Nov 23 22:45:00 CST 2015, time=2015-11-23, status=1, ipAttribution=)]
    2015-11-23 lovetcm

    电解质等没有影响?

    0

相关威廉亚洲官网

Kidney Int:透析患者骨折风险增加

美国与澳大利亚学者联合研究显示,高骨折率及骨折所致不良预后的增加为透析患者造成了严重的健康损失。研究7月31日在线发表于Kidney International杂志。   研究纳入透析预后与实践模式研究(DOPPS)中接受血液透析患者34579例。   结果为,入组患者的骨折发生率为3%。不同国家的骨折发生率不同:其中,发生率最低为日本(12/1000患者-年),最高为比利时(45

Stroke:血液透析患者缺血性卒中的发病率和病死率较高

    终末期肾病(ESRD)需要血液透析治疗,但该治疗方法比正常肾功能增加了10倍脑卒中的风险。来自一般人群的危险因素和管理策略的知识可能并不适用于这些终末期肾病患者。研究人员进行了一项大规模终末期肾病人群的研究来确定脑卒中的风险因素和预后。       从2007年1月1日到2012年12月31日所有接受血液透析的ESRD成年患者参与

AJKD:上臂中部周径下降与血液透析患者的全因死亡率和心血管事件明显相关

一项Hemodialysis(HEMO)研究发现,上臂中部周径(MAC)下降与血液透析(HD)患者的全因死亡率和心血管事件明显相关,这种相关性在体重指数(BMI)低的患者中更加显着(BMI≤25)。该研究由新墨西哥大学Mark L. Unruh和同事完成,已在线发表于American Journal of Kidney Diseases 研究概述 研究共纳入1846名HD患者,观察两项营养状态

CJASN:急性肾衰患者透析能使患者生存获益(倾向匹配分析)

美国学者研究发现,对于血清肌酐有较大程度升高的急性肾损伤(AKI)患者,起始透析与生存率升高相关,相反,对于血清肌酐较低的AKI患者,起始透析与死亡率升高相关。论文4月7日在线发表于《美国肾脏病学会临床杂志》(Clin J Am Soc Nephrol)。 研究纳入严重AKI患者6119例,其中602例接受了透析治疗。研究结果表明,经倾向性评分匹配后,透析与非透析两组患者间的协变量均衡良好,

NDT:降低终末期肾病透析患者感染的风险综述

如何降低终末期肾病(ESRD)透析患者感染的风险一直是肾脏专科和临床科室所关注的问题。英国伦敦皇家医院的Collier S教授等对此作了简短而精辟的综述,并发表在2014年10月的Nephrology Dialysis Transplantation杂志上。 透析患者感染的原因继心血管疾病之后,感染性疾病是导致透析患者死亡的最常见原因。日本透析治疗学会报告称相比日本的总人群死亡率,2008至2

JASN:高透析率β阻滞剂或增透析者死亡风险

β受体阻滞剂一般用于透析患者减少心脏猝死风险。近期加拿大学者进行了相关研究。结果表明,在长期血液透析患者中,与低透析率β受体阻滞剂相比,高透析率β受体阻滞剂可能导致死亡风险显著升高。论文10月30日在线发表于《美国肾脏病学会杂志》(J Am Soc Nephrol)。 此项基于人群的回顾性队列研究共纳入6588例长期接受透析治疗的受试者,其中β阻滞剂高、低透析率组各纳入3294例患者,该